ESR1 and breast carcinoma: Brechbuhl and colleagues recently showed that subtypes of CAFs exist in luminal breast cancer, and CD146-negative CAFs decrease the expression levels of estrogen receptor (ER) in ER-positive breast cancer cells and promote resistance to tamoxifen.